Combination adjuvants drive long lived plastic Th17 cells that convert to multi-functional Th1 cells and protect mice against fungal infection

This study demonstrates that adjuvant formulations containing glucopyranosyl lipid adjuvant (GLA) induce plastic Th17 cells to convert into polyfunctional Th1 memory cells, thereby providing robust protection against fungal infections in mice.

The Gist

The Big Picture: Building a Better Fungal Shield

Imagine your body is a fortress, and fungi (like the one that causes Blastomycosis) are invaders trying to break down the walls. For a long time, scientists knew that the "Th1" soldiers (a specific type of immune cell) were the best at fighting these fungal invaders. They produce a powerful weapon called IFN-γ (Interferon-gamma) that acts like a heavy artillery strike.

However, there was a problem: Scientists didn't know how to train the immune system to make enough of these Th1 soldiers to create a long-lasting shield. They tried, but the protection didn't last long enough.

Meanwhile, another type of soldier, the Th17, was known to be good at fighting fungi too, but they were seen as a different, less "powerful" type of unit. Scientists were puzzled: How do we get the best of both worlds?

The Breakthrough: The "Chameleon" Soldiers

This study discovered a secret trick: Th17 soldiers can actually change their uniforms and become super-powered Th1 soldiers.

Think of it like a special training camp. When you give the immune system a specific vaccine (the "Bl-Eng2" antigen) mixed with a special booster called GLA (Glucopyranosyl Lipid Adjuvant), something magical happens:

1. The Recruitment: The vaccine recruits a large group of Th17 soldiers.
2. The Transformation: Over time, as the initial battle winds down, these Th17 soldiers don't just disappear. Instead, they undergo a "metamorphosis." They shed their old Th17 identity and transform into Polyfunctional Th1 cells.
3. The Super-Soldiers: These new Th1 cells aren't just firing one weapon (IFN-γ). They are now multi-tasking powerhouses that fire three weapons at once: IFN-γ, TNF, and GM-CSF. This triple-threat attack is what makes them so effective at destroying the fungus.

The Analogy: The "Swiss Army Knife" vs. The "Screwdriver"

• The Old Way: Imagine trying to fix a complex machine (the fungal infection) using only a screwdriver (Th1 cells). It works, but it's slow, and you might need to keep buying new screwdrivers because they wear out quickly.
• The New Way (This Study): The researchers found a way to train the immune system to create a Swiss Army Knife.
  • First, they recruit a basic tool (Th17).
  • Then, using the GLA booster, they upgrade that tool into a Swiss Army Knife (Polyfunctional Th1).
  • This Swiss Army Knife has a screwdriver, a knife, and a can opener all in one. It can handle the fungus much better and, crucially, it stays sharp for a very long time (up to a year or more in the study).

The Key Findings in Plain English

1. Long-Lasting Protection: Mice vaccinated with this special mix were protected against fungal infection for at least one year. That's a lifetime for a mouse!
2. The Magic Ingredient (GLA): The secret sauce was adding GLA to the vaccine. Without it, the Th17 cells stayed as Th17s or died off. With it, they transformed into the super-protective Th1 cells.
3. The Transformation Happens Early: The scientists found that this transformation happens before the mice even get sick again. It happens during the "resting phase" after vaccination. The immune system is essentially prepping its elite squad while the body is calm, so they are ready to fight immediately if the fungus returns.
4. Proof of Concept: When the scientists took these "transformed" cells from a vaccinated mouse and put them into a sick, unvaccinated mouse, the sick mouse got better. This proved that these specific cells are the heroes responsible for the cure.

Why Does This Matter?

Currently, there are no licensed vaccines for fungal infections in humans. This is a huge problem because fungal infections are becoming more common and harder to treat, especially in people with weak immune systems.

This paper suggests a new blueprint for making fungal vaccines. Instead of trying to force the body to make Th1 cells directly, we should use adjuvants (boosters) like GLA to encourage the body to make flexible Th17 cells that naturally evolve into the ultimate Th1 defenders.

In short: The researchers found a way to teach the immune system to turn its "good" soldiers into "elite" soldiers that can fight fungi for a very long time, offering hope for a future human fungal vaccine.

Technical Summary

1. Problem Statement

• Lack of Fungal Vaccines: Despite the clinical need, no fungal vaccines are currently licensed for human use.
• Immunological Gap: While Th1 cells (producing IFN-γ) are widely accepted as the cornerstone of antifungal immunity, strategies to harness them are limited by a poor understanding of how to optimally promote their development.
• The Th1/Th17 Paradox: Previous studies established a requisite role for Th17 cells in fungal resistance, yet Th1 cells are also critical. The mechanism reconciling the roles of both subsets, particularly how Th17 cells might transition to protective Th1 phenotypes, remained unclear.
• Durability: Existing subunit vaccines (e.g., Bl-Eng2) show protection but often lack long-term durability or fail to induce the specific polyfunctional T-cell profiles required for sustained immunity.

2. Methodology

The study utilized a murine model of Blastomyces dermatitidis (Bd) infection to evaluate a novel subunit vaccine formulation.

• Antigen & Adjuvants:
  • Antigen: Recombinant Blastomyces-Eng2 (Bl-Eng2), a glycoprotein with potent antigenic and adjuvant properties.
  • Delivery System: Glucan-chitin particles (GCP).
  • Adjuvant Combinations: The study compared three formulations:
    1. Advax3 + Bl-Eng2: Drives a polarized Th1 response (TLR9 agonist CpG).
    2. GCP + Bl-Eng2: Drives a mixed Th1/Th17 response.
    3. GCP + Bl-Eng2 + GLA: Drives a pronounced Th17 response (GLA = Glucopyranosyl lipid adjuvant, a TLR4 ligand).
• Experimental Design:
  • Vaccination: C57BL/6 mice received three subcutaneous (SC) vaccinations, two weeks apart.
  • Challenge: Mice were challenged intratracheally with wild-type Bd yeast.
  • Timepoints: Immune responses were analyzed at peak expansion (Day 14), contraction (3 months), and long-term memory (12 months).
  • Fate Mapping: IL-17A-Cre x Rosa26-eYFP reporter mice were used to permanently label cells that had ever expressed IL-17A, allowing researchers to track the conversion of Th17 cells into other lineages.
  • Adoptive Transfer: eYFP+ (IL-17 lineage) T cells were sorted from vaccinated donors and transferred into naïve recipients to test sufficiency of protection.
  • Cytokine Neutralization: In vivo neutralization of IL-17, IFN-γ, TNF, and GM-CSF was performed to determine the relative contribution of each cytokine to protection.
• Assays: Flow cytometry (tetramer staining, intracellular cytokine staining for IFN-γ, IL-17, TNF, GM-CSF), ELISA, fungal burden quantification (CFU), and survival analysis.

3. Key Contributions

• Discovery of Plasticity: The paper demonstrates that Th17 cells are not terminally differentiated in this context but are "plastic," capable of converting into polyfunctional Th1 cells.
• Adjuvant Synergy: It identifies that the combination of GCP and the TLR4 agonist GLA is superior to single-adjuvant formulations in generating durable, protective immunity.
• Mechanism of Conversion: The study pinpoints that the conversion of Th17 to Th1 occurs during the contraction/memory phase (resting period after vaccination) rather than during the acute infection phase.
• Polyfunctionality as a Marker: It establishes that high-level protection relies not just on IFN-γ, but on polyfunctional Th1 cells co-producing IFN-γ, TNF, and GM-CSF.

4. Key Results

• Long-Term Protection: Vaccination with GCP-Bl-Eng2 induced durable immunity lasting at least 12 months. Mice vaccinated with the GCP + GLA combination showed significantly higher survival rates and lower lung fungal burdens (CFU) compared to GCP alone or Advax3 controls after a 12-month rest period.
• Shift in Phenotype:
  • At peak expansion (Day 14), GCP+GLA induced a balanced 1:1 Th1:Th17 ratio.
  • By 3 months and 12 months, the ratio shifted dramatically to 6:1 (Th1:Th17).
  • The addition of GLA significantly increased the number of T cells producing three cytokines (IFN-γ + TNF + GM-CSF).
• Th17 to Th1 Conversion (Fate Mapping):
  • Using IL-17-eYFP reporter mice, the authors found that ~50% of the IFN-γ-producing T cells in the GLA-vaccinated group originated from the IL-17 lineage (eYFP+).
  • These converted cells were polyfunctional (producing IFN-γ, TNF, and GM-CSF).
  • Timing: The conversion occurred during the 3-month resting period (contraction phase) in the spleen, before re-challenge, rather than during the secondary expansion in the lung.
• Adoptive Transfer: Transferring eYFP+ (IL-17 lineage) memory T cells from vaccinated donors into naïve mice conferred protection against lethal fungal infection, proving these cells are sufficient for immunity.
• Cytokine Dependency: Neutralizing IL-17 or IFN-γ alone reduced protection, but combined neutralization of IFN-γ, TNF, and GM-CSF completely abolished protection, confirming that polyfunctionality is critical.

5. Significance

• Vaccine Development: This work provides a blueprint for designing next-generation antifungal vaccines. It suggests that inducing a transient Th17 response via TLR4 agonists (like GLA) can "seed" a population of plastic cells that mature into highly effective, polyfunctional Th1 memory cells.
• Redefining Th17 Role: It challenges the rigid classification of Th17 cells as solely inflammatory or pathogenic, highlighting their role as a reservoir for long-term protective Th1 immunity.
• Durability: The findings explain how to achieve long-lasting immunity (up to 1 year in mice) by leveraging the epigenetic plasticity of T cells during the memory phase.
• Therapeutic Implications: The identification of polyfunctional Th1 cells (IFN-γ/TNF/GM-CSF) as the correlate of protection offers a specific target for evaluating vaccine efficacy and developing immunotherapies against intracellular pathogens.

In summary, the paper demonstrates that combination adjuvants (specifically GLA) drive the generation of plastic Th17 cells that naturally convert into polyfunctional Th1 memory cells during the contraction phase, providing robust and durable protection against fungal infection.